Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 36 min ago
Peer-reviewedCC BY-NC 4.0Patient Related Outcome Measures

TURALIO Risk Evaluation and Mitigation Strategy Program: 6-year retrospective hepatic safety assessment

  1. 1Clinical Safety & Pharmacovigilance, Daiichi Sankyo, Inc, Basking Ridge, NJ, USA
  2. 2Epidemiology, Daiichi Sankyo, Inc, Basking Ridge, NJ, USA
  3. 3Global Oncology Medical Affairs, Daiichi Sankyo, Inc, Basking Ridge, NJ, USA

Abstract

Aims: To assess hepatic safety for adults with pexidartinib-treated tenosynovial giant cell tumor (TGCT) from the 6-year retrospective evaluation of the TURALIO® Risk Evaluation and Mitigation Strategy (tREMS) Program.

Methods: Retrospective hepatic safety data (08/2019–08/2025) were collected from healthcare professionals and patients in the tREMS Program.

Results: During the current reporting period (06/2024–08/2025), 133/145 (91.7%) new patients received ≥1 pexidartinib dispense. For the cumulative 6-year reporting period, 878/929 (94.5%) patients received ≥1 pexidartinib dispense. Overall, 51/878 (5.8%) patients had adverse events or laboratory abnormalities suggesting serious and potentially fatal liver injury; of these, 47 (92.2%) discontinued pexidartinib, 3 (5.9%) interrupted doses, and 1 (2.0%) continued at the same dose. By August 2025, 34 (66.7%) events were fully resolved, 6 (11.8%) were resolving, 9 (17.6%) were unresolved, and 2 (3.9%) had unknown outcomes. There were no cases of irreversible liver injury, additional cases of vanishing bile duct syndrome, or new safety signals during the current reporting period.

Conclusions: The tREMS Program effectively mitigates hepatotoxicity risk through prompt intervention/reporting and timely dose modifications for adverse event management. When used according to guidelines, pexidartinib is a therapeutic option for adults with symptomatic TGCT associated with severe morbidity or functional limitations and not amenable to improvement with surgery.

Related

  1. Diagnostic performance, implementation fidelity, and costs of the World Health Organization three-test HIV testing strategy in Malawi: a national retrospective evaluation
    T. Chimpandule, H. Tweya, L. Goeke +5
    medRxivPreprintCC BYFull textInfectious diseasemedRxiv
  2. Improving the detection, assessment, management and prevention of delirium in palliative care units (the DAMPen-Delirium II study): protocol for an implementation-to-target Type III hybrid effectiveness-implementation cluster randomised-controlled trial, economic evaluation and process evaluation of the Creating Learning Environments for Compassionate Care-Palliative (CLECC-Pal) implementation strategy.
    Gillian Jackson, Grant Constable, Bronwen Williams +13
    Implementation science : ISPeer-reviewedCC BYFull textGeneral medicineEurope PMCDOAJ
  3. Evaluation of a severity-based surgical strategy for refractory Mooren’s ulcer: A retrospective series with long-term follow-up
    Minghai Huang, Zhifeng Wu, Dongmei Wei +4
    PLOS OnePeer-reviewedCC BY 4.0Full textPhysiologySurgery & anaesthesiaPLOS
  4. Ocular tissue distribution of Ocular Surface Immune Globulins Following Topical and Subconjunctival Administration: A Novel Strategy for Mitigation of ADC-Associated Ocular Toxicity
    Zeenal Dabre, Emily G. Krupa, Bhuvanachandra Pasupuleti +8
    Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and TherapeuticsPeer-reviewedLicence not statedFull text1 citedGeneral medicinePMC
  5. Coated or chewable aspirin and a hybrid air pollution mitigation strategy in patients with atherosclerotic disease: rationale and design of the COATED-AIR randomized trial
    Behnood Bikdeli, Azita H Talasaz, Hooman Bakhshandeh +41
    European Heart Journal. Cardiovascular PharmacotherapyPeer-reviewedCC BY 4.0Full text2 citedCardiovascular medicinePMC
BibTeX
@article{rajper2026turalio,
  title = {{TURALIO Risk Evaluation and Mitigation Strategy Program: 6-year retrospective hepatic safety assessment}},
  author = {Abdul Waheed Rajper and Charles Dharmani and Lalitha Chilakapati and Oluwatosin Fofah and Margaret J. Wooddell},
  journal = {Patient Related Outcome Measures},
  year = {2026},
  month = nov,
  doi = {10.1080/1179271x.2026.2757394},
  url = {https://doi.org/10.1080/1179271x.2026.2757394},
  note = {CC BY-NC 4.0},
}
RIS
TY  - JOUR
TI  - TURALIO Risk Evaluation and Mitigation Strategy Program: 6-year retrospective hepatic safety assessment
AU  - Abdul Waheed Rajper
AU  - Charles Dharmani
AU  - Lalitha Chilakapati
AU  - Oluwatosin Fofah
AU  - Margaret J. Wooddell
PY  - 2026
DA  - 2026/11/05
JO  - Patient Related Outcome Measures
DO  - 10.1080/1179271x.2026.2757394
UR  - https://doi.org/10.1080/1179271x.2026.2757394
AB  - Aims: To assess hepatic safety for adults with pexidartinib-treated tenosynovial giant cell tumor (TGCT) from the 6-year retrospective evaluation of the TURALIO® Risk Evaluation and Mitigation Strategy (tREMS) Program.  Methods: Retrospective hepatic safety data (08/2019–08/2025) were collected from healthcare professionals and patients in the tREMS Program.  Results: During the current reporting period (06/2024–08/2025), 133/145 (91.7%) new patients received ≥1 pexidartinib dispense. For the cumulative 6-year reporting period, 878/929 (94.5%) patients received ≥1 pexidartinib dispense. Overall, 51/878 (5.8%) patients had adverse events or laboratory abnormalities suggesting serious and potentially fatal liver injury; of these, 47 (92.2%) discontinued pexidartinib, 3 (5.9%) interrupted doses, and 1 (2.0%) continued at the same dose. By August 2025, 34 (66.7%) events were fully resolved, 6 (11.8%) were resolving, 9 (17.6%) were unresolved, and 2 (3.9%) had unknown outcomes. There were no cases of irreversible liver injury, additional cases of vanishing bile duct syndrome, or new safety signals during the current reporting period.  Conclusions: The tREMS Program effectively mitigates hepatotoxicity risk through prompt intervention/reporting and timely dose modifications for adverse event management. When used according to guidelines, pexidartinib is a therapeutic option for adults with symptomatic TGCT associated with severe morbidity or functional limitations and not amenable to improvement with surgery.
SN  - 1179-271X
ER  -